Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation [TheStreet.com]
Virax Biolabs Group Limited - Ordinary Shares (VRAX)
Company Research
Source: TheStreet.com
LONDON March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights: Within the scope of approval, ISO 13485:2016 covers the design and development of immunological assay components and kits, including antibody- and peptide-based reagents, for IVD applications. Within the scope of approval, ISO 9001:2015 covers the provision of manufacturing, design and development of Virax's research-use-only products and services. ISO 13485 and ISO 9001 are internationally recognised quality management standards that establish a framework for design control, risk management, traceability, supplier qualification and manufacturing consistency. In simple term
Show less
Read more
Impact Snapshot
Event Time:
VRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRAX alerts
High impacting Virax Biolabs Group Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
VRAX
News
- Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders [Yahoo! Finance]Yahoo! Finance
- Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersPR Newswire
- Virax Biolabs Group (VRAX) had its "sell (e+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationPR Newswire
VRAX
Sec Filings
- 4/14/26 - Form 6-K
- 4/10/26 - Form 6-K
- 3/31/26 - Form 3
- VRAX's page on the SEC website